research use only

17-Hydroxyprogesterone Estrogen/progestogen Receptor agonist

Name: 17-Hydroxyprogesterone
Brand: Selleck Chemicals
SKU: S4507
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S4507

17-Hydroxyprogesterone (17-OHP) is an endogenous progestogen as well as chemical intermediate in the biosynthesis of other steroid hormones, including the corticosteroids and the androgens and the estrogens.

Chemical Structure

Molecular Weight: 330.46

Jump to

Quality Control

Batch: S450701 DMSO]66 mg/mL]false]Ethanol]66 mg/mL]false]Water]Insoluble]false Purity: 99.94%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS
Datasheet

99.94

Related Targets	Adrenergic Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR
Other Estrogen/progestogen Receptor Inhibitors	Elacestrant (RAD1901) Dihydrochloride MPP dihydrochloride Cholesterol Endoxifen HCl G15 Chrysin Licochalcone A AZD9496 PHTPP Liquiritigenin

Solubility

In vitro
Batch:

DMSO : 66 mg/mL (199.72 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 66 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	330.46	Formula	C₂₁H₃₀O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	68-96-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Mechanism of Action

In vitro	17α-OHP is an agonist of the progesterone receptor (PR) similarly to progesterone, albeit weakly in comparison. It is a chemical intermediate in the biosynthesis of steroid hormones, including the androgen and estrogen sex hormones and the glucocorticoids and mineralocorticoids.
In vivo	17-Hydroxyprogesterone is a potent steroid inducer of GVBD (germinal vesicle breakdown).
References	[1] https://pubmed.ncbi.nlm.nih.gov/26027156/ [2] https://pubmed.ncbi.nlm.nih.gov/18060946/ [3] http://jast.modares.ac.ir/article_4639_2ab9bc40c1d9100ade7d633dc7a30924.pdf

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06402344	Recruiting	Hormones; Abuse\|Cardiovascular Diseases	Hospital Israelita Albert Einstein	May 27 2024	--
NCT05907291	Recruiting	Congenital Adrenal Hyperplasia\|Classic Congenital Adrenal Hyperplasia	Crinetics Pharmaceuticals Inc.	July 3 2023	Phase 2
NCT05669950	Recruiting	Congenital Adrenal Hyperplasia	H. Lundbeck A/S	December 19 2022	Phase 1
NCT05299554	Enrolling by invitation	Congenital Adrenal Hyperplasia	Diurnal Limited	April 1 2022	Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):